## Massimo Milione

## List of Publications by Citations

Source: https://exaly.com/author-pdf/2970522/massimo-milione-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93 papers

2,309 citations

26 h-index

46 g-index

98 ext. papers

2,809 ext. citations

avg, IF

4.48 L-index

#	Paper	IF	Citations
93	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12, 1083-92	5.7	317
92	Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 838-43	6.9	225
91	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. <i>Neuroendocrinology</i> , <b>2017</b> , 104, 85-93	5.6	137
90	Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. <i>Gastroenterology</i> , <b>2002</b> , 123, 68-85	13.3	129
89	Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. <i>Molecular Oncology</i> , <b>2016</b> , 10, 253-71	<sub> </sub> 7·9	77
88	Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases. <i>Neuroendocrinology</i> , <b>2017</b> , 104, 112-125	5.6	72
87	Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. <i>Cancer Research</i> , <b>2015</b> , 75, 3636-49	10.1	66
86	Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 50, 61-67	14.4	64
85	Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. <i>Cancer</i> , <b>2003</b> , 98, 1273-82	6.4	59
84	Endocrine tumours of the stomach. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , <b>2005</b> , 19, 659-73	2.5	56
83	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocrine-Related Cancer, <b>2018</b> , 25, 583-593	5.7	55
82	ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 374-82	6.7	50
81	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 111-24	5.7	48
80	Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. <i>Neuroendocrinology</i> , <b>2009</b> , 89, 223-30	5.6	41
79	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 404-413	3.1	40
78	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , <b>2014</b> , 19, 845-50	5.7	37
77	Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2746-2761	7.5	37

## (2016-2018)

76	Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 878-884	3.1	36	
75	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , <b>2018</b> , 155, 479-489.e7	13.3	36	
74	Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. <i>Targeted Oncology</i> , <b>2011</b> , 6, 65-8	5	34	
73	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , <b>2017</b> , 73, 74-84	7.5	32	
72	Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 380-5	3.3	31	
71	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. <i>Oncology</i> , <b>2013</b> , 84, 191-9	3.6	27	
70	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 2858	4.9	26	
69	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 125	8.5	26	
68	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 167-175	3.1	26	
67	Serous psammocarcinoma of the ovary: a case report and review of literature. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 259-62	4.9	24	
66	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. <i>Journal of Controlled Release</i> , <b>2019</b> , 308, 44-56	11.7	23	
65	Microscopic esophagitis and Barrettß esophagus: the histology report. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43 Suppl 4, S319-30	3.3	23	
64	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50	7.5	22	
63	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. <i>Neuroendocrinology</i> , <b>2020</b> , 110, 616-629	5.6	22	
62	mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	21	
61	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 4222-4230	3.1	19	
60	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , <b>2016</b> , 12, 1251-60	3.6	19	
59	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , <b>2016</b> , 11, 337-43	5	18	

58	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , <b>2015</b> , 32, 182	3.7	18
57	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , <b>2014</b> , 9, e92147	3.7	17
56	Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. <i>Hormone Research in Paediatrics</i> , <b>2006</b> , 65, 120-5	3.3	17
55	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , <b>2019</b> , 5, 217-226	5.3	16
54	Imaging of leiomyosarcoma of the inferior vena cava: comparison of 2 cases and review of the literature. <i>Cancer Imaging</i> , <b>2010</b> , 10, 80-4	5.6	16
53	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation. <i>Histopathology</i> , <b>2014</b> , 64, 1014-26	7.3	15
52	Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas. <i>Neuroendocrinology</i> , <b>2005</b> , 81, 311-21	5.6	15
51	Pleomorph poorly differentiated endocrine carcinoma of the rectum. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2003</b> , 442, 605-10	5.1	13
50	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 955-965	8.7	10
49	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. <i>BMC Cancer</i> , <b>2018</b> , 18, 652	4.8	10
48	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , <b>2015</b> , 11, 1947-59	3.6	9
47	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal</i> <i>Cancer</i> , <b>2017</b> , 16, e191-e198	3.8	9
46	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1704-1712	7.5	9
45	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 475-489	5.6	9
44	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 14288	4.9	8
43	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , <b>2014</b> , 86, 289-94	3.6	8
42	Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality. <i>Oncologist</i> , <b>2017</b> , 22, 359	5.7	7
41	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e179-e190	3.8	7

40	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , <b>2013</b> , 30, 610	3.7	7
39	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , <b>2017</b> , 57, 512-517	4	6
38	Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6
37	Synchronous carcinosarcoma of the intrapancreatic bile duct and carcinoma in situ of wirsung duct: a case report. <i>Pancreas</i> , <b>2008</b> , 36, 95-7	2.6	6
36	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 164-174	7.5	6
35	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 145-154	7.5	6
34	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 78-88	7.5	5
33	Teaching Digital Pathology: The International School of Digital Pathology and Proposed Syllabus. Journal of Pathology Informatics, <b>2017</b> , 8, 27	4.4	5
32	Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
31	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 34-43.e6	3.8	5
30	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , <b>2017</b> , 13, 1677-1683	3.6	4
29	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 969-76	3.5	4
28	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. <i>Cancers</i> , <b>2012</b> , 4, 808-20	6.6	4
27	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , <b>2013</b> , 99, e148-51	1.7	4
26	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102583	2.2	4
25	G3 GEP NENs category: are basic and clinical investigations well integrated?. <i>Endocrine</i> , <b>2018</b> , 60, 28-30	4	3
24	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , <b>2009</b> , 3, 79-87	4.3	3
23	Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. <i>Oncology Research</i> , <b>2011</b> , 19, 403-6	4.8	3

22	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820927271	4.7	3
21	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 161-169	4.9	3
20	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. <i>Endoscopy</i> , <b>2016</b> , 48 Suppl 1 UCTN, E40-1	3.4	3
19	IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. <i>Endocrine</i> , <b>2017</b> , 58, 360-367	4	2
18	Gastroblastoma in Adulthood-A Rarity among Rare Cancers-A Case Report and Review of the Literature. <i>Case Reports in Pathology</i> , <b>2019</b> , 2019, 4084196	0.9	2
17	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
16	Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2969-2988	7.9	2
15	Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?. <i>Oncologist</i> , <b>2020</b> , 25, e1257-e1258	5.7	1
14	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
13	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 780716	5.3	1
12	Giant condyloma acuminatum of the anorectum: successful radical surgery with anal reconstruction. <i>Tumori</i> , <b>2011</b> , 97, 805-7	1.7	1
11	Update on Therapeutic Strategy in Lung Carcinoids. <i>Journal of Cancer Therapy</i> , <b>2013</b> , 04, 1466-1471	0.2	1
10	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. <i>Transplantation</i> , <b>2021</b> , 105, 2579-2586	1.8	1
9	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. <i>Molecular Therapy</i> , <b>2021</b> , 29, 2963-2978	11.7	1
8	Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. <i>Pathologica</i> , <b>2021</b> , 113, 12-18	1.9	1
7	Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , 33, e13000	3.8	1
6	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , <b>2019</b> , 15, 3015-3024	3.6	O
5	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 6283	24 <sup>5.3</sup>	O

## LIST OF PUBLICATIONS

- BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications..

  4 Critical Reviews in Oncology/Hematology, 2022, 103647
- Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.. *Endocrine Pathology*, **2022**, 1
- 2 Prognostic Factors: Molecular Pathway (Somatostatin Receptors **2018**, 119-125
- New Concepts in Pathology **2021**, 21-36